Drug development

North America Cell-based Assays Market Report 2022: Featuring Becton, Dickinson, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche & More - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Disease, National Cancer Institute, Non-Hodgkin lymphoma, Kidney, Prostate cancer, Drug development, Biomedical Research, Melanoma, Country, Colon, Pancreatic cancer, Cancer, Skin, Endometrial cancer, Lung, Thyroid cancer, Drug discovery, Bladder cancer, Breast cancer, Liver cancer, GPCR, Comprehension, Product-service system, Leukemia, Medicinal plants

The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • These assays include cell viability assays, cell proliferation assays, and GPCR assays.
  • These high-throughput assays speed up the process of drug discovery by giving the most promising candidate in the biological context that matters the most.
  • The US market dominated the North America Cell-based Assays Market by Country in 2021; thereby, achieving a market value of $7.2 billion by 2028.

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Retrieved on: 
Friday, January 13, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Infection, Therapy, Patent, TSX, FDA, Metronidazole, Drug development, Patient, Prescription, Pharming, Recurrence, Pharmaceutical industry

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501 , Appili’s liquid oral reformulation of the antibiotic metronidazole.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501 , Appili’s liquid oral reformulation of the antibiotic metronidazole.
  • A notice of allowance is issued by the USPTO to indicate that the application has passed the examination.
  • Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections.
  • “We are pleased with this notice of allowance for a new patent that will further strengthen ATI-1501’s potential as a more convenient antibiotic treatment option,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics.

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure

Retrieved on: 
Thursday, January 12, 2023
Research, Technology, Health Technology, Professional Services, Software, Biometrics, Biotechnology, Pharmaceutical, Health, Science, Coronavirus Scientific Advisory Board (Turkey), DSS, Hepatotoxicity, Pharma, Simulations Plus, FDA, Risk, Drug development, Partnership, Patient, Software, SLP, DSX, QST, Medical device

Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).

Key Points: 
  • Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).
  • DSX represents a great advance in that it simplifies the use of the software and greatly increases the speed with which it provides results.
  • This will enable much wider adoption of the software by Pharma, regulators, and academics.”
    Dr. Brett Howell , president of the DILIsym Services division, added: “DILIsym is increasingly being used for high impact applications in the safety space.
  • For the past 12 years, the DILIsym Services division has coordinated the DILI-sim Initiative, which is a public-private partnership that has guided development of the DILIsym software package.

Outlook on the RNA Analysis Global Market to 2028 - Featuring Illumina, Bio-Rad Laboratories, Eurofins Scientific and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Biotechnology, Genetics, Health, Classification, Genome, Gene expression, RNA, Phenotype, Toxicity, RNA transfection, DNA, Personalized medicine, Molecular biology, Orthornavirae, Microarray, Biomarker, Collection, Transcriptome, Research, Vaccine, Gene, Drug development, Protein, RNA-Seq, Application, MicroRNA, Drug discovery, Cancer, CVD, Data analysis, Real-time, Real, Toxicology, Healthcare

The Global RNA Analysis Market size is expected to reach $28 billion by 2028, rising at a market growth of 15.6% CAGR during the forecast period.

Key Points: 
  • The Global RNA Analysis Market size is expected to reach $28 billion by 2028, rising at a market growth of 15.6% CAGR during the forecast period.
  • The method used to produce RNA in a lab setting from a DNA template is known as in vitro transcription.
  • For use in procedures like in vitro translation, the investigation of RNA viruses, and RNA: protein interaction investigations, RNA is produced from DNA templates using in vitro transcription devices.
  • For use in RNA analysis research, single-stranded RNA probes, microgram amounts of specified RNA transcripts, and antisense RNA are all prepared using riboprobe systems.

MMS Named a Great Place to Work in India

Retrieved on: 
Thursday, January 12, 2023
Data Management, Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Medical Devices, Research, Science, Human Resources, Clinical Trials, MMS, Human, Human resources, Culture, Drug development, Feedback, Fine chemical, Management

MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work by the Great Place to Work Institute of India.

Key Points: 
  • MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work by the Great Place to Work Institute of India.
  • Over 87% of MMS employees completed the survey, and based on their feedback, MMS was recognized as demonstrating the excellent workplace culture needed for success.
  • “We are honored to be named a Great Place to Work in India, especially because our colleagues determined the result,” said Uma Sharma , Ph.D., Chief Executive Officer at MMS.
  • With a global footprint across four continents, including offices in Bangalore and Hyderabad, MMS maintains one of the highest retention rates in the industry.

Global Hormone Replacement Therapy Market 2022: A $25+ Billion Market by 2027 - Industry Trends, Growth, Impact of Inflation, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Health, Pharmaceutical, Disease, Ageing, Pfizer, HRT, National Library of Medicine classification, Osteoporosis, UN, Hormone replacement therapy, Health Canada, Availability, Menopause, Flash, Estradiol, Fatigue, Risk, Muscle, Thyroid, Drug development, Degenerative disease, Woman, Weight gain, Patient, Prevalence, Mindfulness, National library, Uterus, Hypothyroidism, Prescription, Disorder, Theramex, Progesterone, Growth hormone, Incidence, Breast cancer, Pharmaceutical industry, Birth control, Frontier, Type, Growth, Testosterone

The "Hormone Replacement Therapy Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hormone Replacement Therapy Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Hormone Replacement Therapy Market is expected to reach US$ 25.09 Billion by 2027 from US$ 18.04 Billion in 2022, growing with a CAGR of 6.82% during 2022-2027.
  • According to the UN, the global population will grow by 8.5 billion in 2030 and 9.7 billion in 2050.
  • Based on Type, hormone replacement therapy is categorized into Estrogen, Human Growth, Thyroid, Testosterone, and Progestogen.

Global eClinical solutions Market Report 2022 to 2028: Rising Adoption of Software Solutions in Clinical Trails Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Technology, Software, Cloud, Hospital, CTMS, COVID-19, Calendar, Maintenance, Drug development, Organization, Marketing, Growth, CDMS, Patient, Clinical data management, Clinical trial, Pharmaceutical industry, Medical imaging

The Global eClinical solutions Market size is expected to reach $20.1 billion by 2028, rising at a market growth of 13.6% CAGR during the forecast period.

Key Points: 
  • The Global eClinical solutions Market size is expected to reach $20.1 billion by 2028, rising at a market growth of 13.6% CAGR during the forecast period.
  • With professional data services as well as the elluminate Clinical Data Cloud, eClinical Solutions assists life sciences enterprises all over the world in accelerating clinical development projects.
  • The eClinical solutions market is concentrating on the development and marketing of software solutions that help speed up and efficiently complete clinical studies.
  • Many integrated eClinical solutions (like CTMS and CDMS) offer clinical researchers end-to-end solutions for all phases of clinical trial administration.

Global Lysosomal Disease Treatment Market Report 2022 to 2028: Featuring Pfizer, Takeda Pharmaceutical, Sanofi and Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Megasphaera, Cell, Lipid, Tissue, National Center for Biotechnology Information, Enzyme replacement therapy, Fabry disease, Government, Type, LSD, Gene, Glycoprotein, Drug development, Diagnosis, Acceleration, National Center for Regenerative Medicine, Prevalence, Radiation, Bone marrow, Disease, Glycogen, Research, Male, Enzyme, Incidence, Glycogen storage disease, Gaucher's disease, Forest Law Enforcement and Governance Program, Pharmaceutical industry, Fabry, Mucopolysaccharidosis

The Global Lysosomal Disease Treatment Market size is expected to reach $11 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

Key Points: 
  • The Global Lysosomal Disease Treatment Market size is expected to reach $11 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.
  • Lysosomal diseases (LSDs) are a complex group of metabolic disorders that are often inherited in an autosomal recessive manner.
  • The primary driving forces in the enzyme replacement therapy market are the expanding research and development for lysosomal disease diagnosis and drug development for treatment.
  • The increasing incidence of lysosomal disease will be a key factor contributing to the acceleration of the market's growth rate.

Global Small Molecule Contract Development and Manufacturing Organization Market Report 2023: Increased Demand for Small Molecule Medicines Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Health, Pharmaceutical, Molecule, Disease, Drug development, CDMO, Incidence, Research, Pharmaceutical industry

The "Global Small Molecule Contract Development and Manufacturing Organization Market 2021-2031 by Product Type, Service Type, Customer Type, Therapeutic Area, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Small Molecule Contract Development and Manufacturing Organization Market 2021-2031 by Product Type, Service Type, Customer Type, Therapeutic Area, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • Global small molecule contract development and manufacturing organization (CDMO) market will reach $117,920.3 million by 2031, growing by 6.4% annually over 2021-2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures.
  • This 166-page report is based on a comprehensive research of the entire global small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications.
  • The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year.

CRISPR QC Closes Seed Round at $1.6M and Appoints George Bonaros to Board of Directors to Fuel Commercial Growth of Their CRISPR Analytics Platform

Retrieved on: 
Tuesday, January 10, 2023
Technology, Biotechnology, Health, Pharmaceutical, Professional Services, Stem Cells, Research, Data Analytics, Agriculture, Genetics, Health Technology, Natural Resources, Science, Semiconductor, CRISPR, University, Drug development, Food, QC, Gene editing, Quality control, University of California, San Diego, Video game console, Pharmaceutical industry, Science

On January 9th 2023, CRISPR QC has announced that they have closed their Seed Round at $1.6M and appoints George Bonaros to Board of Directors to fuel commercial growth of their CRISPR Analytics Platform.

Key Points: 
  • On January 9th 2023, CRISPR QC has announced that they have closed their Seed Round at $1.6M and appoints George Bonaros to Board of Directors to fuel commercial growth of their CRISPR Analytics Platform.
  • CRISPR QC’s CRISPR Analytics Platform provides new dimensions of data and analytics to CRISPR gene editing that allows their partners to accelerate product development.
  • The seed round funding is being invested to advance commercial development of the CRISPR Analytics Platform and to further enhance data analytics capabilities.
  • At CRISPR QC we utilize our CRISPR Analytics Platform, powered by the CRISPR-Chip™, to optimize and de-risk gene editing outcomes by providing a new form of insight into CRISPR.